Fangda represented Hasten Biopharma in its series A financing led by CBC Group, involving a transaction price of USD315,000,000
Tell others about this press release
The press releases published in this section have been uploaded by law firms. Their content has not been appraised or edited by Law.asia, and no responsibility is taken for the accuracy of the information they contain or any misrepresentation therein. For our independent editorial content, please visit our homepage.
Fangda Partners represented Hasten Biopharma in its series A financing led by CBC Group, involving a transaction price of USD315,000,000. The transaction was closed on March 21, 2023. The Fangda team on this deal was led by partners Diana LI and Sherry XU, and the key team members include Francisco Li, Bingyan Xu, Frank Feng, Candice Xie and Janet Song. The Fangda team handled drafting, reviewing and negotiation of the transaction documents. Hasten Biopharma, which integrates R&D, production and commercial promotion and covers the whole industrial chain, is jointly invested and established by CBC Group, one of the largest healthcare-dedicated investment firms in Asia, Hefei Industry Investment Group and Feidong County, Hefei City.
Join our mailing list for legal news and alerts
Sign up